Navigation Links
Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
Date:9/23/2011

THOUSAND OAKS, Calif., Sept. 23, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that data from XGEVA® (denosumab) and Vectibix® (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.  

"The data being presented at the 2011 European Multidisciplinary Cancer Congress reflect Amgen's ongoing commitment to advancing the understanding of cancer and developing novel therapies to treat it," said Willard H. Dere, M.D., senior vice president and international chief medical officer at Amgen.  "New biomarker analyses for Vectibix reinforce the importance of patient selection when EGFR inhibitors are used in metastatic colorectal cancer, while data from the '147 study demonstrate the potential for XGEVA to be the first treatment to prevent the spread of prostate cancer to the bone."

SELECTED ABSTRACTS OF INTERESTIdentified below are selected abstracts of interest on Amgen research. Updated data will be presented at the meeting.


  • Denosumab and Bone Metastasis-free Survival in Men with Castrate-resistant Prostate Cancer: Subgroup Analyses From an International, Double-blind, Randomized, Phase 3 Trial(Abstract 7003) Proffered Papers Session Genitourinary Malignancies – Prostate Cancer on Sunday, Sept. 25, 9:45 a.m. CEST, Hall A3 Data embargoed until 12:01 a.m. CEST on Sept. 24. Data to be highlighted in EMCC press program on Sept. 24 at 8:00 a.m. CEST, Room K21 (Level 1).


  • Denosumab Treatment for Giant Cell Tumor of Bone (GCTB) in Adolescent Patients: Interim Results from a Phase 2 Study(Abstract 32LBA) Proffered Papers Session, Sarcoma on Tuesday, Sept. 27, 11:00 a.m. CEST, Hall T2


  • Pain Outcomes in a Randomized Phase 3 Clinical Trial of Denosumab vs
    '/>"/>


  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
    2. Amgen to Present at the Morgan Stanley Global Healthcare Conference
    3. Amgen to Present at the Baird Healthcare Conference
    4. Amgen to Present at the Stifel Nicolaus Healthcare Conference
    5. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
    6. Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
    7. Amgen Announces Webcast of 2011 Second Quarter Financial Results
    8. Amgen Resolves G-CSF Patent Litigation With Teva
    9. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
    10. Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
    11. Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)...  InnoPharma, Inc. today announced the first generic launch ... Zyprexa® injection), in Canada.  Olanzapine is indicated for the ... with schizophrenia or bipolar I mania. As ... entered into an agreement with Sandoz Canada Inc., pursuant ... sell, market and distribute Olanzapine Injection in ...
    (Date:7/30/2014)... KISSING, Germany , July 30, 2014 ... single use and computer-assisted ("robotic") colonoscopy system, today announced ... worldwide recognized medical device executive, as a new member ... is a highly respected global visionary in the medical ... as President and Chief Executive Officer at Given Imaging ...
    (Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
    Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3
    ... media worldwide report almost on a weekly basis about ... study finds that olive polyphenols can inactivate one of ... today,s most deadly food poisoning occurrences. ... Western Regional Center, a group of USDA researchers led ...
    ... Aug. 11, 2011 Unilife Corporation ("Unilife" ... UNS) today announced strategic additions to its management team. ... launch of the Unifill ® ready-to-fill (prefilled) syringe ... well as accelerate the commercialization of other pipeline devices ...
    Cached Medicine Technology:Scientists at USDA Says CREAGRI HIDROX® Effective Against Staphylococcus aureus Bacteria and Staphylococcus Enterotoxin A 2Unilife Expands Management Team to Support Business Growth 2Unilife Expands Management Team to Support Business Growth 3Unilife Expands Management Team to Support Business Growth 4Unilife Expands Management Team to Support Business Growth 5Unilife Expands Management Team to Support Business Growth 6
    (Date:7/30/2014)... 2014 Good Neighbor Community Services ... upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , In this segment, ... Services’ vision to redefine the traditional approach to ... services. Through passion, innovation, determination, excellence, and collaboration, ...
    (Date:7/30/2014)... SF Cable, distributor of the highest ... on the internet with guaranteed customer satisfaction announces the ... two colors. These lightning cords are MFI certified to ... quality SF Cable Lightning to USB Cables ... faster charging and syncing. Compatible with the iPhone 5S/5C/5 ...
    (Date:7/30/2014)... Hamilton Facial Plastic Surgery ... Carmel office on July 30th. After months of planning, ... to the state-of-the-art suite, located only steps away from ... allow for one-on-one patient comfort, shorter wait times, and ... Dr. Hamilton’s new office-suite will continue to provide the ...
    (Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long ... , a UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or ...
    (Date:7/30/2014)... York (PRWEB) July 30, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to grow, Bernstein ... voice to those calling for a ban on uterine ... Debra Valverde was diagnosed with leiomyosarcoma following a hysterectomy ... a year of her diagnosis, the aggressive cancer had ...
    Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
    ... to Better ... of Treatment Options, WASHINGTON, Nov. 2 Today, ... organization for interventional cardiology, announced the,launch of Seconds Count, ... for an authoritative resource about cardiovascular disease and,treatment. The ...
    ... Kensey Nash Corporation,(Nasdaq: KNSY ) today announced ... Coherence Domain Reflectometry Guidewire, from Lawrence,Livermore National Security, ... to its chronic total occlusion (CTO) platform.,The patent ... it to sense locations, thickness, and structure of ...
    ... CPR, assistance, measuring pain medication effectiveness, improving cancer ... ... A novel way to treat cancer,has won the top honor at the ... Fame Foundation. Ian,Cheong of Johns Hopkins University was announced as the grand ...
    ... of the time,that sales people should be spending with the ... Pharmaceutical sales directors agree the answer is ,too much time, ... - or 6 weeks per rep,per year - is unnecessary ... recent research study by Best Practices, LLC. But yet,understanding and ...
    ... LAWRENCE, Mass., Nov. 2 NxStage Medical, Inc.,(Nasdaq: ... portable,kidney dialysis machine, today announced its financial results for ... the third quarter of 2007 were $11.6 million, compared ... increase of 111%. Revenues in,the chronic home dialysis market ...
    ... demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, PRINCETON, ... results of a 14-day Phase 1 multiple ascending,dose monotherapy study of ... being presented as a "late-breaker" abstract at,the 58th Annual Meeting of ...
    Cached Medicine News:Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 2Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 3Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 4Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 5Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:NxStage Medical Reports Third Quarter 2007 Results 2Health News:NxStage Medical Reports Third Quarter 2007 Results 3Health News:NxStage Medical Reports Third Quarter 2007 Results 4Health News:NxStage Medical Reports Third Quarter 2007 Results 5Health News:NxStage Medical Reports Third Quarter 2007 Results 6Health News:NxStage Medical Reports Third Quarter 2007 Results 7Health News:NxStage Medical Reports Third Quarter 2007 Results 8Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5
    ... Plus Instrument for applications ... ,The VERSASTEP™ Plus ... working length is a ... utilizing radial dilation. It ...
    ... system device is comprised of the following ... access port are also packaged in the ... cone with 12 mm Step™ cannula assembly ... 12 mm locking cone with 10/12 mm ...
    ... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
    ... The Premium One-Step™ single-use system device is ... ,The device components for creating each access ... configurations: , Step™ insufflation and access ... packaged separately. , Step™ radially expandable sleeve, ...
    Medicine Products: